Anti-Human CSF2 Recombinant Antibody (Lenzilumab) (CAT#: TAB-H44)

Figure 1 GM-CSF blockade helps control CART19 toxicities and may improve efficacy.

A) CART19 and lenzilumab treated CART19 and lenzilumab treated CART19 are equally effective in survival outcomes in a high tumor burden NALM6 relapse model compared to UTD (untransduced T cells) (7-8 mice per group, n=2) B-D) Lenzilumab & anti-mouse GM-CSF antibody controlled CRS induced weight loss, neutralized serum human GM-CSF, and reduced expression of serum mouse MCP-1 (monocyte chemoattractant protein-1) in a primary ALL xenograft CART19 CRS/NT model (3 mice per group, * p<0.05). E) Lenzilumab & anti-mouse GM-CSF antibody reduced brain inflammation as shown by MRI in a primary ALL XENOGRAFT CART19 CRS/NT model (3 mice per group, * p<0.05, ** p<0.01).F-G) CART19 + Lenzilumab & anti-mouse GM-CSF antibody treated mice showed reduced CD19+ brain leukemic burden and reduced percentage of brain macrophages in a primary ALL xenograft CART19 CRS/NT model (3 mice per group) H) CRISPR Cas9 K/O of GM-CSF reduces its expression via intracellular staining in CART19 and UTD with NALM6 stimulation.

Sterner, R. M., Sakemura, R., Yang, N., Cox, M. J., Khadka, R., Forsman, C. L.,... & Welch, B. M. (2019). GM-CSF Blockade during Chimeric Antigen Receptor T-Cell (CART) Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance CART Effector Functions. Biology of Blood and Marrow Transplantation, 25(3), S4.

Figure 1 Anti-Human CSF2 Recombinant Antibody (TAB-H44) in WB

Western blot analysis of TAB-H44 with human CSF2.
Lane1: Reducing antigen (0.1 μg)
Lane2: Reducing antigen (0.3 μg)
Lane3: Reducing antigen (0.6 μg)

Figure 2 Anti-Human CSF2 Recombinant Antibody (TAB-H44) in ELISA

ELISA analysis of MRO-1214LC was performed by coating with human CSF2.

Figure 3 Anti-Human CSF2 Recombinant Antibody (TAB-H44) in SDS-PAGE

SDS-PAGE analysis of TAB-H44 in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 180 kDa.

Figure 4 Anti-Human CSF2 Recombinant Antibody (TAB-H44) in SEC-HPLC

SEC-HPLC analysis of TAB-H44 shows that the purity is more than 95%.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl